Quantcast

Global Multiple Sclerosis (MS) Therapeutics Market Report

April 11, 2014

DUBLIN, April 11, 2014 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/btp9ds/global_multiple) has announced the
addition of the “Global Multiple Sclerosis (MS) Therapeutics Market Report”
[http://www.researchandmarkets.com/research/btp9ds/global_multiple ] report to their
offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow
at a CAGR of 3.16 percent over the period 2012-2016. One of the key factors contributing
to this market growth is the rising diagnosis and treatment rates. The Global MS
Therapeutics market has also been witnessing the emergence of biomarkers. However, the
lack of therapies available to manage the progression of the disease could pose a
challenge to the growth of this market.

The report, the Global Multiple Sclerosis (MS) Therapeutics Market Report, has been
prepared based on an in-depth market analysis with inputs from industry experts. The
report covers the market in the Americas, and the EMEA and APAC regions; it also covers
the Global MS Therapeutics market landscape and its growth prospects in the coming years.
The report also includes a discussion of the key vendors operating in this market.

Currently, there is an increase in the adoption of biomarkers that are 100 percent
specific to RRMS conditions. The use of biomarkers proves to be a sensitive indicator of
the slightest disease activity in MS patients. A highly specific protein biomarker for MS
aids in quick and precise identification of patients with the disease, possibly before
clinically relevant symptoms arise. Thus, the use of biomarkers helps prevent the
significant neurodegeneration associated with the disease.

Recently, the Global MS market has witnessed various collaborations for MS biomarkers.
Regulus Therapeutics and Biogen Idec entered into a collaboration to identify blood-based
microRNAs as biomarkers for MS. It is believed by both partners that microRNA biomarkers
aid in the selection of ideal patient segments in clinical trials and also in monitoring
disease progression or relapse.

According to the report, one of the main drivers is the increase in the diagnosis and
treatment of multiple sclerosis
[http://www.researchandmarkets.com/research/btp9ds/global_multiple ]. This is because of
the usage of the latest revised McDonald diagnostic criteria in the treatment of MS. The
McDonald diagnostic criteria consist of a combination of clinical, imaging, and
paraclinical tests used in the diagnosis of MS. This latest revision has helped in
improving the detection of the symptoms of the disease. A McDonald diagnostic criterion
helps improve the sensitivity from around 46 percent to 74 percent. This indirectly aids
in diagnosing MS more rapidly than in the early days.

Further, the report states that one of the major challenges in the market is the lack
of therapies for the management of the progressive form of the disease. The patients under
this category take only symptomatic treatment to improve their quality of life.

        Key Topics Covered:

        1. Executive Summary
        2. List of Abbreviations
        3. Introduction
        4. Market Research Methodology
        5. Scope of the Report
        6. Market Landscape
        7. Geographical Segmentation
        8. Rate of Incidence and Prevalence
        9. Vendor Landscape
        10. Buying Criteria
        11. Market Growth Drivers
        12. Drivers and their Impact
        13. Market Challenges
        14. Impact of Drivers and Challenges
        15. Market Trends
        16. Other Reports in this Series

Companies Mentioned:

        - AB Science
        - Abbvie Inc.
        - Active Biotech AB
        - Astra Zeneca plc
        - Bayer HealthCare AG
        - Biogen Idec Inc.
        - Glaxo Smith Kline plc
        - Glenmark Pharmaceuticals Ltd.
        - Hoffmann-La Roche Inc.
        - Merck Serono SA
        - Novartis AG
        - Sanofi SA.
        - Teva Pharmaceutical Industries Ltd.

For more information visit

http://www.researchandmarkets.com/research/btp9ds/global_multiple

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus